The global pharmaceutical contract development and manufacturing market is projected to reach USD 171.3 billion by 2026 from USD 120.6 billion in 2021, at a CAGR of 7.3% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
The global pharmaceutical contract development and manufacturing market is highly consolidated. Key players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland). Acquisitions and product launches are the key growth strategies undertaken by these companies to maintain their positions in the market.
To know about the assumptions considered for the study download the pdf brochure
Lonza (Switzerland): The company offers integrated solutions to the pharmaceutical, biotech, consumer health, and specialty chemicals markets. As a contract development and manufacturing organization (CDMO), the company provides integrated solutions with various technologies that span the whole pharma value chain—from molecule to patient. The major end users of Lonza’s services include pharmaceutical companies, biotechnology companies, government research institutes, consumer & healthcare product manufacturers, formulators, and service companies. In 2021, Lonza majorly adopted agreement and partnership as major strategy to develop services related to vaccines for COVID-19 and other biologics manufacturing services. Lonza focused on geographical expansions in 2020, with major focus on its HPAPI, Capsugel, and bioconjugation-based services. During the ongoing COVID-19 pandemic, Lonza has been at the forefront and entered into agreements and partnerships with various other US-based firms to expedite the manufacturing process for COVID vaccines and drugs. These initiatives by the company are expected to help Lonza retain its leadership position in the market.
Thermo Fisher Scientific (US): Thermo Fisher is another prominent player operating in the pharmaceutical contract development and manufacturing market. The company has a strong geographic footprint serving over 400,000 customers in pharmaceutical and biotech companies.
In 2021, Thermo Fisher acquired Henogen S.A. and, Novaseps contract viral vector manufacturing services in Belgium for vaccines and therapies. These acquisitions significantly strengthened the company’s presence in North America & Europe. Thermo Fisher also has an extensive distribution channel across the globe. In 2020, the company invested USD 1.2 billion in the research & development of new products to cater to the unmet needs in the healthcare industry. The company’s extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services. The company also invested USD 150 million in its Pharma Services business segment to expand its manufacturing capacity for sterile liquid and lyophilized product development & commercial manufacturing.
Catalent (US): Catalent is one of the leading providers of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It mainly focuses on business strategies such as product launches, expansions, acquisitions, partnerships, and collaborations. In 2021, the company focused on acquisition and partnership strategies with cell and gene therapy providers to provide services in cell and gene therapy services. In May 2019, the company launched its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention that took place at the Pennsylvania Convention Center in Philadelphia. Catalent also focuses on investing in its facilities and technologies for further expansion of its manufacturing capabilities. The company invested USD 27 million for the commercialization of its oral disintegrating tablet technology, Zydis Ultra. This technology allows an increased drug load and taste masking to be incorporated into the company’s Zydis ODT dosage form, which is a unique freeze-dried tablet that disperses almost instantly in the mouth without water. Through such innovative investments, the company further focuses on diversifying its offerings and services. Catalent also focuses on expanding its facilities across the globe, strengthening its geographical footprint in the pharmaceutical contract development and manufacturing market.
Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma, CRO)-Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE